Bausch & Lomb IOL deal
This article was originally published in The Gray Sheet
Executive Summary
Eye care giant gains worldwide rights, excluding Japan, to Santen Pharmaceutical's hydrophobic acrylic polymers, which will be used in the development of intraocular lenses. B&L currently markets IOL products including Crystalens, the only FDA-approved accommodating IOL, Akreos and SofPort. The acquisition of Crystalens maker Eyeonics in 2008 marked B&L's entry into the premium IOL market, in which it competes with Alcon and Abbott subsidiary Advanced Medical Optics (1"The Gray Sheet" Jan. 28, 2008, p. 3)
You may also be interested in...
Bausch & Lomb Buys Eyeonics, Enters Premium IOL Market With Crystalens
Bausch & Lomb will enter the fast-growing premium intraocular lens market for the first time through its acquisition of Crystalens maker Eyeonics under a pact announced Jan. 20
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.